Vivos therapeutics announces pricing of $8 million private placement

Littleton, colo., jan. 05, 2023 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company'') (nasdaq: vvos), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (osa) and snoring in adults, today announced that it has entered into a definitive agreement with a single institutional investor to raise approximately $8 million in a private placement offering at a price of $1.20 per unit. each unit consists of one share of common stock (or a pre-funded warrant to purchase one share of common stock) and one warrant exercisable for one share common stock at a price of $1.20 per share for a period of five years and 6 months from closing. no actual units will be issued in the offering.
VVOS Ratings Summary
VVOS Quant Ranking